• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Dexcom Introduces Generative AI Platform for Glucose Biosensing

by Jasmine Pennic 12/17/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Dexcom, the global leader in continuous glucose monitoring (CGM), has achieved another groundbreaking milestone by launching the first generative AI (GenAI) platform in glucose biosensing technology, Stelo. 

– The Stelo platform analyzes individual health data patterns to provide personalized insights and recommendations for improving metabolic health.

AI-Powered Personalized Guidance

The Dexcom GenAI platform leverages Google Cloud’s Vertex AI and Gemini models to analyze user data and generate personalized insights related to diet, exercise, and sleep. This technology enhances Dexcom’s existing Weekly Insights feature, offering users more tailored guidance and support in managing their health.

Stelo: The First GenAI-Enabled CGM

Stelo, Dexcom’s over-the-counter glucose biosensor, is the first product to integrate this GenAI technology. Users will now receive personalized tips, recommendations, and education within the Stelo app, empowering them to make informed decisions about their health.

Key Benefits of Dexcom’s GenAI Platform

  • Personalized Insights: Provides users with tailored guidance based on their individual health data patterns.
  • Improved Metabolic Health: Helps users understand the impact of lifestyle choices on their glucose levels and make informed decisions to improve their metabolic health.
  • Enhanced User Experience: Delivers personalized content and recommendations within the Stelo app, making it easier for users to manage their health.
  • Innovation in Glucose Biosensing: Positions Dexcom as a leader in the integration of AI with CGM technology.

Stelo Expansion Plans

Dexcom plans to expand its GenAI platform across its product portfolio, offering more personalized and insightful health management tools to its millions of users worldwide. This technology has the potential to revolutionize diabetes care and improve the lives of people with metabolic conditions.

“The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader and opens the door for future advancements across our product portfolio,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Innovation is at the core of what we do. We look forward to introducing additional GenAI-powered features over the next year to help users contextualize their health information and make proactive, informed lifestyle decisions.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Continuous Glucose Monitoring (CGM), Dexcom, Diabetes Management, Generative AI

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |